Fusion Antibodies plc
FAB.L · LSE
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | £5,897 | £2,139 | £10,016 | £15,567 |
| - Cash | £359 | £1,199 | £195 | £2,049 |
| + Debt | £20 | £43 | £75 | £69 |
| Enterprise Value | £5,558 | £983 | £9,896 | £13,587 |
| Revenue | £1,965 | £1,136 | £2,901 | £4,799 |
| % Growth | 73% | -60.8% | -39.5% | – |
| Gross Profit | £430 | -£265 | £202 | £1,717 |
| % Margin | 21.9% | -23.3% | 7% | 35.8% |
| EBITDA | -£1,624 | -£2,065 | -£2,483 | -£573 |
| % Margin | -82.6% | -181.8% | -85.6% | -11.9% |
| Net Income | -£1,713 | -£2,226 | -£2,596 | -£1,200 |
| % Margin | -87.2% | -196% | -89.5% | -25% |
| EPS Diluted | -0.018 | -0.04 | -0.1 | -0.046 |
| % Growth | 55.4% | 59.8% | -115.6% | – |
| Operating Cash Flow | -£1,364 | -£1,769 | -£1,755 | -£333 |
| Capital Expenditures | -£10 | -£2 | -£114 | -£258 |
| Free Cash Flow | -£1,374 | -£1,771 | -£1,869 | -£591 |